Coherus BioSciences heads into its third-quarter report with an odd disconnect. Three months ago, management delivered its most confident call in a year, finally putting a number on Loctorsi with full-year 2026 revenue guidance of $57 million to $62 million, after deferring that commitment through three straight quarters. Since then the stock has lost roughly 40% while the S&P 500 slipped about 2%, and at $0.83 it sits just above the $0.81 low of its post-earnings range and far below its 200-day moving average of $1.53. The operating story improved; the market went the other way. This report has to explain which one is right.
The Street is looking for revenue of $15.9 million, up about 37% from $11.6 million a year ago and roughly 11% above the $14.3 million posted last quarter. That sequential step sits squarely inside management's long-running promise of 10% to 15% quarterly demand growth, a target it has reiterated on four consecutive calls. It also lines up with the stated goal of reaching about $15 million per quarter during 2026. In other words, consensus is not asking for heroics, only for the trajectory management has described to keep showing up. A print near $16 million keeps the full-year range credible; a quarter that stalls near last quarter's level would leave a steep fourth-quarter climb and invite questions about whether guidance was set too generously on its first try. The loss is expected to hold at $0.22 per share, matching last quarter and well better than the $0.38 loss a year earlier.
The details behind the revenue number matter as much as the total. Last quarter management pointed to the most new patient starts since launch, noted that more than half of addressable physicians still have not prescribed Loctorsi, and flagged a duration-of-therapy opportunity from correcting physicians who dose on a less frequent schedule or stop before progression. Evidence that new prescribers are coming on and that patients are staying on drug longer would validate that framing. A new pilot with an AI-driven physician education platform and messaging built around six-year Jupiter-02 survival data are supposed to support that effort, while competition in head and neck from EGFR-targeted and antibody-drug conjugate agents remains the risk that could quietly cap growth.
The balance sheet is the other pressure point, and likely a big part of the stock's slide. Cash and investments fell to $105.3 million last quarter from $167 million, with about $39 million of that drop tied to one-time transition services payments from the divestiture rather than ongoing burn. Management said remaining legacy obligations, including $22.7 million of transition payables, should be largely settled by year end. Investors should look for cash usage this quarter that reflects continued SG&A and R&D discipline, consistent with the $170 million to $175 million full-year operating expense outlook, and a clear line of sight to burn stopping on those legacy items. The first $37.5 million Udenica earn-out milestone, missed in the second quarter but still eligible in the third, is a meaningful swing factor. Hitting it would add non-dilutive cash at a moment when the share price makes equity raises painful; missing again would sharpen financing worries.
Sentiment has cooled, with bullish readings easing to about 27% from 34% ahead of the last report, which fits a stock trading near its lows. That lowers the bar in one sense, but a company priced under a dollar gets little benefit of the doubt. Management will also have its first earnings forum to put the October pipeline disclosures for TAGMO in head and neck and the Casdozo liver cancer triplet into commercial and strategic context.
Ultimately, the narrative stays intact only if Loctorsi grows in line with the 10% to 15% cadence and management can show the cash runway bridging to its 2027 goal of roughly $30 million in quarterly sales. Steady growth paired with clearer funding visibility, ideally helped by the Udenica milestone, would challenge the market's skepticism. Anything less would suggest the selloff was reading the risks correctly.